CClinicalTrials.gg
Status unknownNCT03502369Updated Apr 19, 2018

Ultrasound Guided Quadratus Lumborum Block for Post Operative Analgesia After Hip Arthroplasty

An interventional study of Anterior Quadratus lamborum block in Pain, Postoperative, sponsored by Alexandria University. Status unknown at 1 site in Egypt. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-04-19.

Sponsored by Alexandria University · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

The study evaluates the effectiveness of anterior quadratus lumborum block for post operative analgesia after hip arthroplasty. Half of the participants will receive ultrasound guided anterior quadratus lumborum block using 30ml bupivacaine 0.375%, while the other half will not receive the block ( control group).

Read the detailed description

Sensory innervation of the hip region involves branches of the lumbar plexus and sacral plexus. Effective post operative analgesia can be approached by blocking the lumbar plexus at the level of the quadratus lumborum muscle. Quadratus lumborum block has several approach methods (anterior, lateral, posterior, and intramuscular). Anterior quadratus lumborum block also known as transmuscular QL block or QL3, the local anaesthetic (30ml of bupivacaine 0.375%) is injected between the psoas major muscle (PM) and the quadratus lumborum muscle (QL). Therefore, the anterior quadratus lumborum block may generate analgesia from T10 to L4 covering the sensory innervation of the hip region.

02

Conditions studied

  • Pain, Postoperative

Browse trials for

03

In context

Pain, Postoperative

5,089 studies on the registry are indexed under Pain, Postoperative; 1,137 are open to participants now.

This study's planned enrollment of 90 is above the median of 75 across 4,341 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

Alexandria University is the lead sponsor of 569 studies on the registry; 125 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • American society of anesthesiologists physical status \|-\|\|\| , scheduled to undergo unilateral hip replacement via lateral approach.

Exclusion criteria

Exclusion Criteria:

  • patient refusal.
  • History of neurological/neuromuscular, psychiatric, dementia preventing proper comprehension.
  • coagulation disorders.
  • History of allergy to the study medication.
  • Infection overlying the injection site.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    QL group

    Anterior Quadratus lumborum block will be done for all patients of these group. Local anaesthetic (30ml of bupivacaine) will be injected in fascial plane between the quadratus lumborum muscle and Psoas major muscle by using the ultrasound.

    Procedure: Anterior Quadratus lamborum block

  • No intervention
    C group

    Patients of these group will be the control group. The will receive acetaminophen 1g every 8h, ketorolac 30mg ever 12h and as required morphine 2mg for post operative analgesia after hip arthroplasty.

Interventions

  • ProcedureAnterior Quadratus lamborum block

    Local anaesthetic will be injected in the fascial plane between psoas major muscle and quadratus lumborum muscle.

    Also known as: Transmuscular QL block, QL3

06

What researchers measure

Primary outcomes

  1. Pain intensity assessment

    Patients will be trained to use visual analogue scale which consists of 10cm line, 0 cm equivalent to no pain and 10 cm denoting the worst imaginable pain.

    Time frame: every hour for the first 4 post operative hours and then every 4 hours for the rest of the 24 post operative hours.

Secondary outcomes

  1. Total amount of post operative morphine (mg).

    Total amount of post operative morphine (mg) used as rescue analgesia and the first time of its request.

    Time frame: any time in the first 24 post operative hours.

Other outcomes

  1. Patient satisfaction.

    Patient satisfaction with pain control will be assessed on a four point scale 1.Excellent 2.Good 3.fair 4.poor

    Time frame: every hour in the first 4 post operative hours and then every 4 hours for the rest of the 24 post operative hours.

07

Study locations

1 of 1 sites recruiting
  • Alexandria faculty of medicine
    Alexandria, 21519, Egypt
    Recruiting
08

References and documents

Publications

  • Ueshima H, Otake H, Lin JA. Ultrasound-Guided Quadratus Lumborum Block: An Updated Review of Anatomy and Techniques. Biomed Res Int. 2017;2017:2752876. doi: 10.1155/2017/2752876. Epub 2017 Jan 3. PubMed 28154824 ↗
  • Sauter AR, Ullensvang K, Niemi G, Lorentzen HT, Bendtsen TF, Borglum J, Pripp AH, Romundstad L. The Shamrock lumbar plexus block: A dose-finding study. Eur J Anaesthesiol. 2015 Nov;32(11):764-70. doi: 10.1097/EJA.0000000000000265. PubMed 26426575 ↗

Individual participant data

Plan to share: Yes — De identified individual participant data for all primary and secondary outcome measures will be made available.

Supporting information: Study protocol, Sap, Icf, Csr, Analytic code

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03502369
Lead sponsor
Alexandria University
Responsible party
Abdullah Gaber (Registeral, Alexandria University) — Principal investigator
First posted
Apr 18, 2018
Start date
Sep 2018 (estimated)
Primary completion
Jan 2019 (estimated)
Completion
Mar 2019 (estimated)
Last update
Apr 19, 2018

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion